首页> 外文期刊>Case Reports in Ophthalmology >Complete Resolution of a Giant Pigment Epithelial Detachment Secondary to Exudative Age-Related Macular Degeneration after a Single Intravitreal Ranibizumab (Lucentis) Injection: Results Documented by Optical Coherence Tomography
【24h】

Complete Resolution of a Giant Pigment Epithelial Detachment Secondary to Exudative Age-Related Macular Degeneration after a Single Intravitreal Ranibizumab (Lucentis) Injection: Results Documented by Optical Coherence Tomography

机译:单次玻璃体内雷珠单抗(Lucentis)注射后继发于年龄相关性渗出性黄斑变性继发的色素沉着性色素上皮脱离的完整分辨率:光学相干断层扫描记录的结果

获取原文
           

摘要

Aim:To describe a patient with a giant pigment epithelial detachment (PED) secondary to exudative age-related macular degeneration (ARMD) successfully treated with a single intravitreal ranibizumab (Lucentis) injection (0.5 mg/0.05 ml).Methods:An 89-year-old woman presented with a six-day history of reduced vision and distortion in the left eye. Best-corrected visual acuity in that eye was 6/15. Fundoscopy revealed a giant PED and exudates temporally to the fovea. Optical coherence tomography showed a PED associated with subretinal and intraretinal fluid. Fluorescein angiography confirmed the diagnosis of an occult choroidal neovascularization. Treatment with intravitreal injections of ranibizumab (Lucentis) was recommended, although the increased risk of retinal pigment epithelium (RPE) rip was mentioned. Results:Four weeks after the first intravitreal Lucentis injection, the visual acuity in the left eye improved to 6/7.5, with a significant improvement of the distortion and a complete anatomical resolution of the PED confirmed by optical coherence tomography. Conclusion:Giant PED secondary to exudative ARMD can be successfully treated with intravitreal ranibizumab, despite the increased risk of RPE rip. To our knowledge, this is the first case presenting with complete resolution of PED after a single ranibizumab injection.
机译:目的:描述一名患者,该患者经一次玻璃体内雷珠单抗(Lucentis)注射液(0.5 mg / 0.05 ml)成功治疗后因年龄相关性渗出性黄斑变性(ARMD)继发巨大色素上皮脱离(PED)。方法:89-岁的老妇出现了六天的视力下降和左眼变形的病史。那只眼睛的最佳矫正视力为6/15。眼底镜检查发现巨大的PED并暂时渗出到中央凹。光学相干断层扫描显示PED与视网膜下和视网膜内液相关。荧光血管造影证实了隐匿性脉络膜新血管形成的诊断。尽管提到了视网膜色素上皮(RPE)撕裂的风险增加,但建议使用玻璃体腔注射兰尼单抗(Lucentis)进行治疗。结果:在第一次玻璃体腔注射Lucentis后的四个星期,左眼视力提高到6 / 7.5,通过光学相干断层扫描确认的畸变和PED的完整解剖分辨率得到了显着改善。结论:尽管RPE撕裂的风险增加,但玻璃体腔注射兰尼单抗仍可成功治疗继发性渗出性ARMD的巨型PED。据我们所知,这是首例雷珠单抗注射后完全分离PED的病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号